Printed from Voxsanity (voxsanity.com.au) — NCT02392572 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lymphoma
Phase 2 Lymphoma Trial, Recruiting
NCT02392572
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have acute leukemia or high-risk myelodysplastic syndrome (a blood/bone marrow disorder) that has come back or stopped responding to treatment, and where standard treatments are not expected to produce a lasting remission
- People aged 18 or older
- People who have a reasonable level of physical functioning (able to carry out daily activities, with or without some limitations)
- Women who could become pregnant must use an approved form of contraception (such as abstinence, an IUD, oral contraceptive pill, or double barrier method like a condom plus diaphragm) for 16 weeks after the last dose of the study drug, and must have a negative pregnancy test within one week before starting treatment
- Sexually active men must use an approved form of contraception for the full time on the study and for at least 16 weeks after the last dose of the study drug
- People who are willing and able to provide written informed consent
- People whose last cancer treatment ended at least 2 weeks ago (for certain drug types) or at least 5 half-lives ago (for other drug types), and who have no significant ongoing side effects from prior treatment
- People with kidney function within an acceptable range (confirm with trial site)
- People with liver function within an acceptable range (confirm with trial site)
- People who had a stem cell transplant more than 6 months ago, with no active transplant-related immune complications, and not currently on high-dose steroids or most immunosuppressive medications for those complications
Who may not be able to join:
- People with serious uncontrolled illnesses, such as an uncontrolled infection, severe heart failure, uncontrolled irregular heartbeat, or a mental health or personal situation that would make it difficult to follow the study requirements
- People with active heart disease, including a heart attack in the past 3 months, significant coronary artery disease, irregular heartbeat not managed by medication, or severe heart failure
- People currently receiving any other standard or experimental treatment for their blood cancer
- People who have been diagnosed with or treated for another type of cancer within the past 3 years (with some exceptions for certain low-risk or non-invasive cancers)
- People with a known history of HIV, hepatitis C, or who carry hepatitis B
- People with active drug use or alcohol dependence
- People whose leukemia has spread to the brain or spinal cord
- People with a white blood cell count above a certain level before starting one of the study drugs (venetoclax) (confirm with trial site)
- People who are currently breastfeeding or pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
3 November 2015
Est. completion
30 November 2026
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Maximum Tolerated Dose (MTD) of ONOC201 in Relapsed or Refractory Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) or Acute Lymphoblastic Leukemia (ALL); Objective Response (OR) (Phase II)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.